Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

Oncotarget

Volumn 5, Issue 7, 2014, Pages 1846-1855

  Piha Paul, Sarina A ^a   Wheler, Jennifer J ^a   Fu, Siqing ^a   Levenback, Charles ^a   Lu, Karen ^a   Falchook, Gerald S ^a   Naing, Aung ^a   Hong, David S ^a   Tsimberidou, Apostolia M ^a   Kurzrock, Razelle ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bevacizumab; Gynecologic malignancy; Temsirolimus

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RAPAMYCIN;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GRADING; CLINICAL ARTICLE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; GYNECOLOGIC CANCER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; UTERUS CANCER; VAGINA CANCER; ANALOGS AND DERIVATIVES; BLOOD; CARCINOMA; CHEMICALLY INDUCED; CLINICAL TRIAL; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; SECONDARY; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; BEVACIZUMAB; CARCINOMA; FATIGUE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; MUCOSITIS; NEUTROPENIA; OVARIAN NEOPLASMS; SIROLIMUS; THROMBOCYTOPENIA; UTERINE CERVICAL NEOPLASMS;

EID: 84899011208     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1834     Document Type: Article

References (51)

1. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J and Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005; 11(9):3514-3522.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-1186.
3. Hicklin DJ and Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23(5):1011-1027.
4. Rowe DH, Huang J, Kayton ML, Thompson R, Troxel A, O'Toole KM, Yamashiro D, Stolar CJ and Kandel JJ. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg. 2000; 35(1):30-32; discussion 32-33.
5. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69 Suppl 3:4-10.
6. Ferrara N, Hillan KJ and Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005; 333(2):328-335.
7. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005; 69 Suppl 3:11-16.
8. Ferrara N and Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438(7070):967-974.
9. Adjei AA and Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005; 23(23):5386-5403.
10. Baselga J and Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23(11):2445-2459.
11. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol. 2001; 19(2):257-262.
12. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004; 5(1):13-17.
13. Choi KS, Bae MK, Jeong JW, Moon HE and Kim KW. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol. 2003; 36(1):120-127.
14. Lee JW, Bae SH, Jeong JW, Kim SH and Kim KW. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med. 2004; 36(1):1-12.
15. Linehan WM, Walther MM and Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003; 170(6 Pt 1):2163- 2172.
16. Powis G and Kirkpatrick L. Hypoxia inducible factor- 1alpha as a cancer drug target. Mol Cancer Ther. 2004; 3(5):647-654.
17. Tee AR and Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol. 2005; 16(1):29-37.
18. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P and Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--= hypoxia response element--= VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 2000; 60(22):6248-6252.
19. Welsh SJ and Powis G. Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets. 2003; 3(6):391-405.
20. Yu JL, Rak JW, Coomber BL, Hicklin DJ and Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002; 295(5559):1526-1528.
21. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59(22):5830-5835.
22. Kapoor A. Inhibition of mTOR in kidney cancer. Curr Oncol. 2009; 16 Suppl 1:S33-39.
23. Rai JS, Henley MJ and Ratan HL. Mammalian target of rapamycin: a new target in prostate cancer. Urol Oncol. 28(2):134-138.
24. Oda K, Stokoe D, Taketani Y and McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005; 65(23):10669-10673.
25. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21(1):99-102.
26. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G and Milella M. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006; 66(11):5549-5554.
27. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R and McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007; 25(33):5180- 5186.
28. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE and Eisenhauer EA. Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. J Clin Oncol.
29. Piha-Paul S. "An Innovative Phase I Trial Design Allowing for the Identification of Multiple Potential Maximum Tolerated Doses with Combination Therapy of Targeted Agents" (2010). UT GSBS Dissertations and Theses. Paper 72. http://digitalcommons.library.tmc.edu/utgsbs_ dissertations/72.
30. Cancer Therapy Evaluation Program CTCfAE, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish Date: August 9, 2006.
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228-247.
32. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007; 25(13):1760-1764.
33. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670):554.
34. Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ and Luthra R. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009; 22(8):1023-1031.
35. Chow LM and Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006; 241(2):184-196.
36. Engelman JA, Luo J and Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-619.
37. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB and De Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 17(20):6563-6573.
38. Maehama T and Dixon JE. The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-13378.
39. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS and Kurzrock R. A phase I trial of liposomal Doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 17(21):6840-6846.
40. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-562.
41. Luo J, Manning BD and Cantley LC. Targeting the PI3KAkt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4(4):257-262.
42. Catalogue of Somatic Mutations in Cancer. Wellcome Trust Sanger Institute. http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic/
43. Wu X, Senechal K, Neshat MS, Whang YE and Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1998; 95(26):15587-15591.
44. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S and Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 10(3):558-565.
45. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido- Laguna I, Luthra R, Lee JJ, Lu KH and Kurzrock R. PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. J Clin Oncol.
46. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE and Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008; 99(8):1265-1268.
47. Sato T, Nakashima A, Guo L, Coffman K and Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 29(18):2746-2752.
48. Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M and Tamanoi F. Point mutations in TOR confer Rhebindependent growth in fission yeast and nutrientindependent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A. 2007; 104(9):3514-3519.
49. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R and Ellenson LH. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997; 57(18):3935-3940.
50. Piha-Paul SA, Cohen PR and Kurzrock R. Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol. 29(26):e727-730.
51. Piha-Paul SA, Hong DS and Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J Clin Oncol. 29(12):e333-335.